Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma
ID Number 08-0508
Principal Investigator(s)Josep Llovet
Department(s) or Division(s)
Liver Diseases
Description
The purpose of this study is to determine if the study drug, sorafenib, is effective at reducing the risk of liver cancer returning, after a recent procedure to remove the cancer.
Contact Information
Tanisha Brown
(212) 241-4028
tanisha.brown@mssm.edu
Recruiting Patients: Yes